ALKERMES INC (ALKS) is a publicly traded company in the Unknown sector. Across all available filings, 31 corporate insiders have executed 1037 transactions totaling $115.9M, demonstrating a bearish sentiment with -$113.0M in net insider flow. The most recent transaction on Feb 23, 2026 involved a transaction of 7,689 shares valued at $0.
No significant insider buying has been recorded for ALKS in the recent period.
No significant insider selling has been recorded for ALKS in the recent period.
Based on recent SEC filings, insider sentiment for ALKS is bearish with an Insider Alignment Score of 1/100 and a net flow of -$113.0M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ALKERMES INC (ALKS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 31 insiders are actively trading ALKS stock, having executed 1037 transactions in the past 90 days. The most active insider is Richard F. Pops (Executive), who has made 124 transactions totaling $98.4M.
Get notified when executives and directors at ALKS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Option Exercise | 7,689 | $N/A | $0 | |
| Feb 23, 2026 | Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Payment | 3,414 | $32.19 | $109.9K | |
| Feb 23, 2026 | Joseph Gaffin David | EVP, CLO, Alkermes, Inc. | Option Exercise | 7,689 | $N/A | $0 | |
| Feb 23, 2026 | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Option Exercise | 7,689 | $N/A | $0 | |
| Feb 23, 2026 | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Payment | 3,414 | $32.19 | $109.9K | |
| Feb 23, 2026 | C. Hopkinson Craig | EVP R&D, Chief Medical Officer | Option Exercise | 7,689 | $N/A | $0 | |
| Feb 23, 2026 | Curtis Jackson Blair | EVP, Chief Operating Officer | Option Exercise | 8,738 | $N/A | $0 | C-Suite |
| Feb 23, 2026 | Curtis Jackson Blair | EVP, Chief Operating Officer | Payment | 3,880 | $32.19 | $124.9K | C-Suite |
| Feb 23, 2026 | Curtis Jackson Blair | EVP, Chief Operating Officer | Option Exercise | 8,738 | $N/A | $0 | C-Suite |
| Feb 23, 2026 | Todd Nichols Christian | SVP, Chief Commercial Officer | Option Exercise | 6,407 | $N/A | $0 | |
| Feb 23, 2026 | Todd Nichols Christian | SVP, Chief Commercial Officer | Payment | 2,845 | $32.19 | $91.6K | |
| Feb 23, 2026 | Todd Nichols Christian | SVP, Chief Commercial Officer | Option Exercise | 6,407 | $N/A | $0 | |
| Feb 23, 2026 | Joseph Parisi Samuel | VP, Finance (Interim PAO) | Option Exercise | 2,283 | $N/A | $0 | |
| Feb 23, 2026 | Joseph Parisi Samuel | VP, Finance (Interim PAO) | Payment | 672 | $32.19 | $21.6K | |
| Feb 23, 2026 | Joseph Parisi Samuel | VP, Finance (Interim PAO) | Option Exercise | 2,283 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 203 | $114.5M | 56.8% |
Exercise(M) | 479 | $54.6M | 27.1% |
Payment(F) | 307 | $31.1M | 15.4% |
Purchase(P) | 7 | $1.4M | 0.7% |
Award(A) | 32 | $0 | 0.0% |
Gift(G) | 9 | $0 | 0.0% |
Insider selling pressure at ALKERMES INC has increased, with 31 insiders executing 1037 transactions across all time. Total sales of $114.5M significantly outpace purchases of $1.4M, resulting in a net outflow of $113.0M. This selling activity appears largely discretionary, which may warrant closer attention from investors.